Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Applied StemCell, Inc. Receives ISO 9001 and ISO 13485 Certification

Applied StemCell,Inc.
Posted on: 06 Nov 17

Applied StemCell, Inc., a global provider of gene editing and stem cell-based services, as well as a leader in molecular and cellular reference standard products for clinical diagnostics markets, is proud to receive certifications for two International Organization for Standardization (ISO) Quality Management Systems (QMS) on October 20, 2017, the ISO 9001:2015 and 13485:2016.

The ISO certification entails extensive documentation and creation of standard operating procedures (SOP) to ensure quality services and products, customer satisfaction, continued improvement in processes, quality and workflow, and conformity to customer and regulatory requirements. The certificate approves Applied StemCell, Inc., located in Milpitas, California (USA), providing gene-editing, stem cell, and reference standard products and services for life science research, preclinical, and clinical diagnostic global markets. In addition, we have also been awarded the ISO 13485 certification for consistently meeting customer and regulatory requirements for products and services related to medical devices, and specifically to our reference standard products.

“We are extremely proud of our team and their efforts to receive both the ISO 9001 and 13485 certifications. This new milestone reinforces Applied StemCell’s mission to offer high quality biotechnology services and products so that our customers can be assured that their expectations are met or exceeded,” stated Dr. Ruhong Jiang, CEO of Applied StemCell, Inc.

With this new resource, Applied StemCell looks forward to dynamically accomplish our mission to equip the research community with the best quality tools for advancing biomedical research and enabling novel and effective therapeutic solutions.

Applied StemCell’s Strategy and Pipeline

Applied StemCell’s strategy is to utilize its core strengths to expand its IP portfolio and develop a strong therapeutic pipeline based on its patented gene editing technologies. The company’s expertise in utilizing genome editing for both animal and cell model generation, as well as its portfolio of improved genome editing technologies, make it uniquely poised to develop transformative solutions to pressing medical challenges.

About Applied StemCell

Applied StemCell, Inc. is a leading stem cell and gene-editing company focused on the development of products and therapeutics that are enabled by its proprietary gene editing platform technologies TARGATT™ and CRISPR/Cas9. For more information, please visit www.appliedstemcell.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171106005276/en/

Business Wire
www.businesswire.com

Last updated on: 06/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.